Long non-coding RNAs in cancer drug resistance development

DNA Repair

Volumn 45, Issue , 2016, Pages 25-33

  Majidinia, Maryam ^a,b   Yousefi, Bahman ^b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer; Chemotherapy; Drug resistance; lncRNA

Indexed keywords

LONG UNTRANSLATED RNA; ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE; DNA REPAIR; DRUG METABOLISM; DRUG TRANSPORT; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MOLECULAR DYNAMICS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RNA STRUCTURE; RNA SYNTHESIS; SIGNAL TRANSDUCTION; CARCINOGENESIS; DRUG INACTIVATION; DRUG RESISTANCE; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL TRANSPORT; CARCINOGENESIS; CELL CYCLE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INACTIVATION, METABOLIC; NEOPLASMS; RNA, LONG NONCODING; SIGNAL TRANSDUCTION;

EID: 84978886863     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2016.06.003     Document Type: Review

References (100)

1. [1] Ferreira, R.J., dos Santos, D.J., Ferreira, M.-J.U., P-glycoprotein and membrane roles in multidrug resistance. Future Med. Chem. 7 (2015), 929–946.
2. [2] Kathawala, R.J., Gupta, P., Ashby, C.R., Chen, Z.-S., The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist. Updat. 18 (2015), 1–17.
3. [3] Mallini, P., Lennard, T., Kirby, J., Meeson, A., Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat. Rev. 40:3 (2014), 341–348.
4. [4] Wu, Q., Yang, Z., Nie, Y., Shi, Y., Fan, D., Peroxisome proliferator-activated receptors and their ligands in cancer drug resistance: opportunity or challenge. Anticancer Agents Med. Chem., 16, 2016, 10.2174/1871520616666160204112941.
5. [5] A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Cojoc, M., Mäbert, K., Muders, M.H., Dubrovska, A., (eds.) Seminars in Cancer Biology, 2015, Elsevier.
6. [6] Mora, A., Taranta, M., Zaki, N., Cinti, C., Capobianco, E., Epigenetically driven network cooperativity: meta-analysis in multi-drug resistant osteosarcoma. J. Complex Netw., 2015 (cnv017).
7. [7] Fang, X.-y., Pan, H.-f., Leng, R.-x., Ye, D.-q., Long noncoding RNAs: novel insights into gastric cancer. Cancer Lett. 356 (2015), 357–366.
8. [8] Iyer, M.K., Niknafs, Y.S., Malik, R., Singhal, U., Sahu, A., Hosono, Y., et al. The landscape of long noncoding RNAs in the human transcriptome. Nat. Genet., 2015.
9. [9] Yu, X., Li, Z., Long non-coding RNA HOTAIR: a novel oncogene (review). Mol. Med. Rep. 12 (2015), 5611–5618.
10. [10] Rinn, J.L., Chang, H.Y., Genome regulation by long noncoding RNAs. Annu. Rev. Biochem., 81, 2012.
11. [11] Hauptman, N., Glavač, D., Long non-coding RNA in cancer. Int. J. Mol. Sci. 14 (2013), 4655–4669.
12. [12] Mitra, S.A., Mitra, A.P., Triche, T.J., A central role for long non-coding RNA in cancer. Front. Genet., 70, 2012.
13. [13] Gullerova, M., Long non-coding RNA. Genomic Elements in Health Disease and Evolution, 2015, Springer, 83–108.
14. [14] Geisler, S., Coller, J., RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat. Rev. Mol. Cell Biol. 14 (2013), 699–712.
15. [15] Guttman, M., Rinn, J.L., Modular regulatory principles of large non-coding RNAs. Nature 482:7385 (2012), 339–346.
16. [16] Ma, L., Bajic, V.B., Zhang, Z., On the classification of long non-coding RNAs. RNA Biol. 10 (2013), 924–933.
17. [17] Qi, P., Du, X., The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod. Pathol. 26 (2013), 155–165.
18. [18] Zhang, H., Chen, Z., Wang, X., Huang, Z., He, Z., Chen, Y., Long non-coding RNA: a new player in cancer. J. Hematol. Oncol. 6 (2013), 1–7.
19. [19] Harries, L., Long non-coding RNAs and human disease. Biochem. Soc. Trans., 40, 2012, 902.
20. [20] Kornienko, A.E., Guenzl, P.M., Barlow, D.P., Pauler, F.M., Gene regulation by the act of long non-coding RNA transcription. BMC Biol., 11, 2013, 59.
21. [21] Lee, J.T., Epigenetic regulation by long noncoding RNAs. Science 338 (2012), 1435–1439.
22. [22] Mercer, T.R., Mattick, J.S., Structure and function of long noncoding RNAs in epigenetic regulation. Nat. Struct. Mol. Biol. 20 (2013), 300–307.
23. [23] Moran, V.A., Perera, R.J., Khalil, A.M., Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res. 40 (2012), 6391–6400.
24. [24] Lee, J.T., Bartolomei, M.S., X-inactivation, imprinting, and long noncoding RNAs in health and disease. Cell 152 (2013), 1308–1323.
25. [25] Nie, L., Wu, H.-J., Hsu, J.-M., Chang, S.-S., LaBaff, A.M., Li, C.-W., et al. Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. Am. J. Trans. Res., 4, 2012, 127.
26. [26] Natoli, G., Andrau, J.-C., Noncoding transcription at enhancers: general principles and functional models. Annu. Rev. Genet. 46 (2012), 1–19.
27. [27] Guil, S., Esteller, M., Cis-acting noncoding RNAs: friends and foes. Nat. Struct. Mol. Biol. 19 (2012), 1068–1075.
28. [28] Ørom, U.A., Shiekhattar, R., Long noncoding RNAs usher in a new era in the biology of enhancers. Cell 154 (2013), 1190–1193.
29. [29] Guttman, M., Amit, I., Garber, M., French, C., Lin, M.F., Feldser, D., et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458 (2009), 223–227.
30. [30] Guttman, M., Garber, M., Levin, J.Z., Donaghey, J., Robinson, J., Adiconis, X., et al. Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. Nat. Biotechnol. 28 (2010), 503–510.
31. [31] Kung, J.T., Colognori, D., Lee, J.T., Long noncoding RNAs: past, present, and future. Genetics 193 (2013), 651–669.
32. [32] Wang, K.C., Chang, H.Y., Molecular mechanisms of long noncoding RNAs. Mol. Cell 43 (2011), 904–914.
33. [33] Bonasio, R., Tu, S., Reinberg, D., Molecular signals of epigenetic states. Science 330 (2010), 612–616.
34. [34] Hung, T., Chang, H.Y., Long noncoding RNA in genome regulation: prospects and mechanisms. RNA Biol. 7 (2010), 582–585.
35. [35] Lee, J.T., Lessons from X-chromosome inactivation: long ncRNA as guides and tethers to the epigenome. Genes Dev. 23 (2009), 1831–1842.
36. [36] Spitale, R.C., Tsai, M.-C., Chang, H.Y., RNA templating the epigenome: long noncoding RNAs as molecular scaffolds. Epigenetics 6 (2011), 539–543.
37. [37] Good, M.C., Zalatan, J.G., Lim, W.A., Scaffold proteins: hubs for controlling the flow of cellular information. Science 332 (2011), 680–686.
38. [38] Prensner, J.R., Chinnaiyan, A.M., The emergence of lncRNAs in cancer biology. Cancer Discov. 1 (2011), 391–407.
39. [39] Gibb, E.A., Brown, C.J., Lam, W.L., The functional role of long non-coding RNA in human carcinomas. Mol. Cancer 10 (2011), 38–55.
40. [40] Yousefi, B., Rahmati, M., Ahmadi, Y., The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21. Life Sci. 99 (2014), 14–17.
41. [41] Petrovics, G., Zhang, W., Makarem, M., Street, J.P., Connelly, R., Sun, L., et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 23 (2004), 605–611.
42. [42] Ginger, M.R., Shore, A.N., Contreras, A., Rijnkels, M., Miller, J., Gonzalez-Rimbau, M.F., et al. A noncoding RNA is a potential marker of cell fate during mammary gland development. Proc. Natl. Acad. Sci. 103 (2006), 5781–5786.
43. [43] Gupta, R.A., Shah, N., Wang, K.C., Kim, J., Horlings, H.M., Wong, D.J., et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464 (2010), 1071–1076.
44. [44] Lin, R., Maeda, S., Liu, C., Karin, M., Edgington, T., A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 26 (2007), 851–858.
45. [45] Gejman, R., Batista, D.L., Zhong, Y., Zhou, Y., Zhang, X., Swearingen, B., et al. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 93 (2008), 4119–4125.
46. [46] Mourtada-Maarabouni, M., Hedge, V.L., Kirkham, L., Farzaneh, F., Williams, G.T., Growth arrest in human T-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 (GAS5). J. Cell Sci. 121 (2008), 939–946.
47. [47] The enigmatic world of mRNA-like ncRNAs: their role in human evolution and in human diseases. Széll, M., Bata-Csörgő, Z., Kemény, L., (eds.) Seminars in Cancer Biology, 2008, Elsevier.
48. [48] Chung, S., Nakagawa, H., Uemura, M., Piao, L., Ashikawa, K., Hosono, N., et al. Association of a novel long non‐coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 102 (2011), 245–252.
49. [49] Malek, E., Jagannathan, S., Driscoll, J.J., Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget, 5(18), 2014, 8027.
50. [50] Zhou, X., Chen, J., Tang, W., The molecular mechanism of HOTAIR in tumorigenesis, metastasis, and drug resistance. Acta Biochim. Biophys. Sin. 46 (2014), 1011–1015.
51. [51] Salehan, M., Morse, H., DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br. J. Biomed. Sci. 7 (2013), 31–40.
52. [52] Shah, M.A., Schwartz, G.K., Cell cycle-mediated drug resistance an emerging concept in cancer therapy. Clin. Cancer Res. 7 (2001), 2168–2181.
53. [53] Brkic, G., Gopas, J., Tanic, N., Dedovic-Tanic, N., Benharroch, D., Finkelstein-Jaworowsky, E., et al. Genomic instability in drug-resistant human melanoma cell lines detected by Alu-I-arbitrary-primed PCR. Anticancer Res. 23 (2002), 2601–2608.
54. [54] Gan, W., Guan, Z., Liu, J., Gui, T., Shen, K., Manley, J.L., et al. R-loop-mediated genomic instability is caused by impairment of replication fork progression. Genes Dev. 25 (2011), 2041–2056.
55. [55] Skourti-Stathaki, K., Proudfoot, N.J., A double-edged sword: R loops as threats to genome integrity and powerful regulators of gene expression. Genes Dev. 28 (2014), 1384–1396.
56. [56] Aguilera, A., García-Muse, T., R loops: from transcription byproducts to threats to genome stability. Mol. Cell 46 (2012), 115–124.
57. [57] Westover, K.D., Bushnell, D.A., Kornberg, R.D., Structural basis of transcription: separation of RNA from DNA by RNA polymerase II. Science 303 (2004), 1014–1016.
58. [58] Santos-Pereira, J.M., Herrero, A.B., García-Rubio, M.L., Marín, A., Moreno, S., Aguilera, A., The Npl3 hnRNP prevents R-loop-mediated transcription–replication conflicts and genome instability. Genes Dev. 27 (2013), 2445–2458.
59. [59] Xue, X., Yang, Y., Zhang, A., Fong, K., Kim, J., Song, B., et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene, 2015.
60. [60] Wang, Y., Chen, W., Yang, C., Wu, W., Wu, S., Qin, X., et al. Long non-coding RNA UCA1a (CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int. J. Oncol. 41 (2012), 276–284.
61. [61] Huang, J., Zhou, N., Watabe, K., Lu, Z., Wu, F., Xu, M., et al. Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). Cell Death Dis., 5, 2014, e1008.
62. [62] Lee, H., Kim, C., Ku, J.-L., Kim, W., Yoon, S.K., Kuh, H.-J., et al. A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells. Mol. Cells, 37, 2014, 540.
63. [63] Yousefi, B., Samadi, N., Ahmadi, Y., Akt and p53R2, partners that dictate the progression and invasiveness of cancer. DNA Repair (Amst.) 22 (2014), 24–29.
64. [64] Karimian, A., Ahmadi, Y., Yousefi, B., Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst.) 42 (2016), 63–71.
65. [65] Breier, A., Gibalova, L., Seres, M., Barancik, M., Sulova, Z., New insight into p-glycoprotein as a drug target. Anticancer Agents Med. Chem. 13 (2013), 159–170.
66. [66] Vasiliou, V., Vasiliou, K., Nebert, D.W., Human ATP-binding cassette (ABC) transporter family. Hum. Genom., 3, 2009, 281.
67. [67] Tsang, W., Kwok, T., Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene 26 (2007), 4877–4881.
68. [68] Takahashi, K., Yan, I.K., Wood, J., Haga, H., Patel, T., Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol. Cancer Res. 12 (2014), 1377–1387.
69. [69] Zhang, X.-w., Bu, P., Liu, L., Zhang, X.-z., Li, J., Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem. Biophys. Res. Commun., 2015.
70. [70] Wang, Y., Zhang, D., Wu, K., Zhao, Q., Nie, Y., Fan, D., Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol. Cell. Biol. 34 (2014), 3182–3193.
71. [71] Hang, Q., Sun, R., Jiang, C., Li, Y., Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression. Anticancer Drugs 26 (2015), 632–640.
72. [72] Ivanov, M., Kacevska, M., Ingelman-Sundberg, M., Epigenomics and interindividual differences in drug response. Clin. Pharmacol. Ther. 92 (2012), 727–736.
73. [73] Xu, C., Li, C.Y.-T., Kong, A.-N.T., Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28 (2005), 249–268.
74. [74] Peng, L., Paulson, A., Li, H., He, X., Lu, H., Klaassen, C.D., et al. Long noncoding RNAs and transcription of cytochrome P450 s in mouse liver during maturation. FASEB J., 27(1102), 2013, 7.
75. [75] Tsuruo, T., Naito, M., Tomida, A., Fujita, N., Mashima, T., Sakamoto, H., et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 94 (2003), 15–21.
76. [76] R.T. Marquez, B.W. Tsao, N.F. Faust, L. Xu, Drug resistance and molecular cancer therapy: apoptosis versus autophagy. 2013.
77. [77] Zhu, Y., Yu, M., Li, Z., Kong, C., Bi, J., Li, J., et al. ncRAN, a newly identified long noncoding RNA, enhances human bladder tumor growth, invasion, and survival. Urology 77:510 (2011), e1–e5.
78. [78] Tsang, W.P., Wong, T.W., Cheung, A.H., Kwok, T.T., Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. RNA 13 (2007), 890–898.
79. [79] Radisky, D.C., Epithelial-mesenchymal transition. J. Cell Sci. 118 (2005), 4325–4326.
80. [80] Xia, H., Hui, K., MicroRNAs involved in regulating epithelial–mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther. 1 (2012), 723–730.
81. [81] P. Kong, The LncRNA H19 promotes epithelial to mesenchymal transition by functioning as MiRNA sponges in colorectal cancer, 2015.
82. [82] Yousefi, B., Samadi, N., Baradaran, B., Shafiei-Irannejad, V., Zarghami, N., Peroxisome proliferator-activated receptor ligands and their role in chronic myeloid leukemia: therapeutic strategies. Chem. Biol. Drug Des. 88 (2016), 17–25.
83. [83] Saliani, N., Darabi, M., Yousefi, B., Baradaran, B., Khaniani, M.S., Darabi, M., et al. PPARγ agonist-induced alterations in Δ6-desaturase and stearoyl-CoA desaturase 1: Role of MEK/ERK1/2 pathway. World J. Hepatol. 5 (2013), 220–225.
84. [84] Fan, Y., Shen, B., Tan, M., Mu, X., Qin, Y., Zhang, F., et al. Long non‐coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J. 281 (2014), 1750–1758.
85. [85] Yang, Y., Li, H., Hou, S., Hu, B., Liu, J., Wang, J., The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One, 2016, 2013.
86. [86] Xia, Y., He, Z., Liu, B., Wang, P., Chen, Y., Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway. Mol. Med. Rep. 12 (2015), 4530–4537.
87. [87] Zhang, C.-L., Zhu, K.-P., Shen, G.-Q., Zhu, Z.-S., A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma. Tumor Biol., 2015, 1–12.
88. [88] Silveira, R.A., Fachel, A.A., Moreira, Y.B., De Souza, C.A., Costa, F.F., Verjovski-Almeida, S., et al. Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib. Hematology 19 (2014), 31–41.
89. [89] Kino, T., Hurt, D.E., Ichijo, T., Nader, N., Chrousos, G.P., Noncoding RNA Gas5 is a growth arrest and starvation-associated repressor of the glucocorticoid receptor. Sci. Signal., 3(107), 2010 (ra8).
90. [90] Hung, T., Wang, Y., Lin, M.F., Koegel, A.K., Kotake, Y., Grant, G.D., et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat. Genet. 4 (2011), 621–629.
91. [91] Fang, S., Gao, H., Tong, Y., Yang, J., Tang, R., Niu, Y., et al. Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells. Lab. Invest., 2015.
92. [92] Ding, J., Li, D., Gong, M., Wang, J., Huang, X., Wu, T., et al. Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer. Onco Targets Ther., 7, 2014, 1625.
93. [93] Milhem, M.M., Knutson, T., Yang, S., Zhu, D., Wang, X., Leslie, K.K., et al. Correlation of MTDH/AEG-1 and HOTAIR expression with metastasis and response to treatment in sarcoma patients. J. Cancer Sci. Ther., 2011.
94. [94] Zhu, K.-P., Zhang, C.-L., Shen, G.-Q., Zhu, Z.-S., Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int. J. Clin. Exp. Pathol., 8, 2015, 8754.
95. [95] Hou, Z., Xu, C., Xie, H., Xu, H., Zhan, P., Yu, L., et al. Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One, 2014.
96. [96] Wang, Y., Wu, K., Yang, Z., Zhao, Q., Fan, D., Xu, P., et al. Multidrug-resistance related long non-coding RNA expression profile analysis of gastric cancer. PLoS One, 10(8), 2015, e0135461.
97. [97] Redis, R.S., Sieuwerts, A.M., Look, M.P., Tudoran, O., Ivan, C., Spizzo, R., et al. CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget, 4, 2013, 1748.
98. [98] Meijer, D., van Agthoven, T., Bosma, P.T., Nooter, K., Dorssers, L.C., Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol. Cancer Res. 4 (2006), 379–386.
99. [99] Feng, F.Y., Ma, T., Speers, C., Iyer, M.K., Zhao, S., Prensner, J.R., et al. Abstract PD6-1: The long noncoding RNA M41 promotes aggressiveness and tamoxifen resistance in ER-positive breast cancers. Cancer Res., 75, 2015 (PD6-1-PD6-1).
100. [100] Huang, H., Han, Y., Zhang, C., Wu, J., Feng, J., Qu, L., et al. HNRNPC as a candidate biomarker for chemoresistance in gastric cancer. Tumor Biol., 2015, 1–8.